A new paradigm in mechanical circulatory support: 100 patient experience.
Acutely decompensated heart failure presents a complicated challenge. Established temporary support measures have significant adverse effects. A novel minimally invasive temporary left ventricular assist device (LVAD), the Impella 5.0, has been developed to support these patients. Patients from January 2014 to September 2018 at a single center with acutely decompensated heart failure who failed medical management and required additional support using an Impella 5.0 were evaluated in a retrospective manner using a prospectively maintained database. Patients were bridged using the device to recovery (BTR) n=30, durable device (BTDD) n=23, or transplantation (BTT) n=47. All devices were placed using an axillary artery approach. Demographics and outcomes were evaluated for each group and compared. 100 patients underwent insertion of an axillary Impella 5.0. Patients had an average age of 56.7±13.2, were predominantly male (84%), had severely depressed LVEF (average 16%), and the majority were INTERMACS 1 (57%) or 2 (33%). When divided into groups, there was no difference in age or INTERMACS score, but a statistical difference was noted in baseline LVEF (20%, 14%, 15%) and creatinine (1.0, 2.0, 1.6), in BTR, BTDD, or BTT, respectively (all p<0.05). Survival was 64% overall, and 50%, 48%, and 81% for BTR, BTDD, and BTT, respectively (p=0.007). Survival improved during this experience and was 90% overall in the most recent 30 patients. Usage of this minimally invasive LVAD system is an attractive strategy to support patients with acute decompensated heart failure to recovery, durable LVAD, or heart transplant.